Клиническое исследование

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2

NCT: NCT07593209 · RECRUITING

NCT IDNCT07593209

СтатусRECRUITING

Дата начала2026-05-01

Завершение2027-12-31

SponsorFirst Hospital of China Medical University (OTHER)

First posted2026-05-18

Last updated2026-05-18

Краткое описание

Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.

Официальный источник

Открыть на ClinicalTrials.gov →

Данные получены через API ClinicalTrials.gov. Актуальный статус смотрите в официальной записи.